QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
NASDAQ:CNSP

CNS Pharmaceuticals (CNSP) Stock Price, News & Analysis

$0.28
+0.02 (+7.75%)
(As of 02/29/2024 ET)
Today's Range
$0.27
$0.29
50-Day Range
$0.24
$1.28
52-Week Range
$0.23
$4.40
Volume
179,272 shs
Average Volume
462,487 shs
Market Capitalization
$1.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CNSP stock logo

About CNS Pharmaceuticals Stock (NASDAQ:CNSP)

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

CNSP Stock Price History

CNSP Stock News Headlines

Cns Pharmaceuticals Inc (CNSP)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
CNSP CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals Inc Ordinary Shares
CNS Pharmaceuticals Inc Ordinary Shares CNSP
See More Headlines
Receive CNSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CNS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
2/29/2024
Next Earnings (Estimated)
4/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CNSP
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Net Income
$-15,270,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.03 per share

Miscellaneous

Free Float
5,974,000
Market Cap
$1.73 million
Optionable
Not Optionable
Beta
2.65
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report














CNSP Stock Analysis - Frequently Asked Questions

How have CNSP shares performed in 2024?

CNS Pharmaceuticals' stock was trading at $1.27 at the start of the year. Since then, CNSP shares have decreased by 78.1% and is now trading at $0.2780.
View the best growth stocks for 2024 here
.

Are investors shorting CNS Pharmaceuticals?

CNS Pharmaceuticals saw a decrease in short interest in February. As of February 15th, there was short interest totaling 102,600 shares, a decrease of 87.2% from the January 31st total of 802,400 shares. Based on an average daily trading volume, of 335,600 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.3% of the shares of the stock are sold short.
View CNS Pharmaceuticals' Short Interest
.

When is CNS Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024.
View our CNSP earnings forecast
.

How were CNS Pharmaceuticals' earnings last quarter?

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) posted its quarterly earnings data on Tuesday, November, 14th. The company reported ($1.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.73) by $0.65.

When did CNS Pharmaceuticals' stock split?

CNS Pharmaceuticals shares reverse split on the morning of Tuesday, November 29th 2022. The 1-30 reverse split was announced on Tuesday, November 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of CNS Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CNS Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Advanced Micro Devices (AMD), Heat Biologics (HTBX), Roku (ROKU), Aldeyra Therapeutics (ALDX), Salesforce (CRM), Gilead Sciences (GILD), Inseego (INSG), Nokia Oyj (NOK) and Block (SQ).

When did CNS Pharmaceuticals IPO?

(CNSP) raised $9 million in an initial public offering on Friday, November 8th 2019. The company issued 2,100,000 shares at a price of $4.00-$5.00 per share. Benchmark acted as the underwriter for the IPO.

Who are CNS Pharmaceuticals' major shareholders?

CNS Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Armistice Capital LLC (1.96%) and Smith Anglin Financial LLC (0.95%). Insiders that own company stock include Christopher Downs, Jerzy Gumulka, John M Climaco and Waldemar Priebe.
View institutional ownership trends
.

How do I buy shares of CNS Pharmaceuticals?

Shares of CNSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CNSP) was last updated on 2/29/2024 by MarketBeat.com Staff